MI
KWON KIM
Profesor asociado de Ciencias de la Salud
Hospital Clinico Universitario de Valencia
Valencia, EspañaHospital Clinico Universitario de Valencia -ko ikertzaileekin lankidetzan egindako argitalpenak (21)
2024
-
Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 2, pp. 205-217
2023
-
Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy
Transplantation and Cellular Therapy, Vol. 29, Núm. 7, pp. 430-437
-
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
Haematologica, Vol. 108, Núm. 1, pp. 110-121
-
Correction: Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era (Bone Marrow Transplantation, (2023), 58, 6, (673-679), 10.1038/s41409-023-01949-x)
Bone Marrow Transplantation
-
Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study
Transplantation and Cellular Therapy, Vol. 29, Núm. 12, pp. 747.e1-747.e10
-
Prognosis of patients with acute lymphoblastic leukaemia relapsing after allogeneic stem cell transplantation
European Journal of Haematology, Vol. 110, Núm. 6, pp. 659-668
-
Results of haploidentical transplant in patients with donor-specific antibodies: a survey on behalf of the Spanish Group of Hematopoietic Transplant and Cell Therapy
Frontiers in immunology, Vol. 14, pp. 1165759
-
Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era
Bone Marrow Transplantation, Vol. 58, Núm. 6, pp. 673-679
2022
-
Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups
Frontiers in Immunology, Vol. 13
-
Post-Transplantation Cyclophosphamide After HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of GETH-TC
Transplantation and Cellular Therapy, Vol. 28, Núm. 4, pp. 204.e1-204.e10
2021
-
COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey
Leukemia, Vol. 35, Núm. 10, pp. 2885-2894
-
Hospital and outpatient models for Hematopoietic Stem Cell Transplantation: A systematic review of comparative studies for health outcomes, experience of care and costs
PLoS ONE, Vol. 16, Núm. 8 August
-
Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma
Cancer Medicine, Vol. 10, Núm. 10, pp. 3214-3223
-
Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper
Infection, Vol. 49, Núm. 2, pp. 215-231
-
Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide
Bone Marrow Transplantation, Vol. 56, Núm. 10, pp. 2432-2444
2020
2019
-
Allogeneic stem-cell transplantation in HIV-1-infected patients with high-risk hematological disorders
AIDS, Vol. 33, Núm. 9, pp. 1441-1447
2018
-
A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms
Blood Advances, Vol. 2, Núm. 14, pp. 1719-1737
2017
-
Single umbilical cord blood with or without CD341 cells from a third-party donor in adults with leukemia
Blood Advances, Vol. 1, Núm. 15, pp. 1047-1055
2016
-
Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience
Bone Marrow Transplantation, Vol. 51, Núm. 10, pp. 1307-1312